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Summary
The aim of this study was to investigate the expression of the interleukin
(IL)-36 axis in patients with primary Sj€ogren’s syndrome (pSS). Blood
and minor labial salivary glands (MSG) biopsies were obtained from 35
pSS and 20 non-Sj€ogren’s syndrome patients (nSS) patients. Serum IL-
36a was assayed by enzyme-linked immunosorbent assay (ELISA). IL-
36a, IL-36R, IL-36RA, IL-38, IL-22, IL-17, IL-23p19 and expression in
MSGs was assessed by reverse transcription–polymerase chain reaction
(RT–PCR), and tissue IL-36a and IL-38 expression was also investigated
by immunohistochemistry (IHC). ab and gd T cells and CD681 cells
isolated from MSGs were also studied by flow cytometry and confocal
microscopy analysis. IL-36a was over-expressed significantly in the serum
and in the salivary glands of pSS. Salivary gland IL-36a expression was
correlated with the expression levels of IL-17, IL-22 and IL-23p19. IL-38,
that acts as inhibitor of IL-36a, was also up-regulated in pSS. ab1 CD31
T cells and CD681 cells were the major source of IL-36a in minor
salivary glands of pSS. gd T cells were not significantly expanded in the
salivary glands of pSS but produced more IL-17, as their percentage
correlated with the focus score. Higher expression of IL-36a and IL-36R
was also demonstrated in gd T cells isolated from pSS compared to
controls. In this study we demonstrate that a significant increase in
circulating and tissue levels of IL-36a occurs in pSS patients.
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Introduction
Interleukin (IL)-36a, IL-36b, IL-36g and IL-36Ra, collec-
tively called IL-36 cytokines, are novel members of the
IL-1 family of cytokines [1] involved in the development
of human diseases such as psoriasis [2,3]. IL-36Ra and
IL-36 agonists are highly expressed in the psoriatic skin
[4], and anti-tumour necrosis factor (TNF) treatment
results in decreased expression of the IL-36 agonists and
IL-36Ra, with an improved clinical outcome [4]. In psori-
asis, IL-36 seems to exert a proinflammatory role by
mediating the cross-talk between dendritic (DCs) and
skin tissue cells, the recruitment of inflammatory cells
and the expansion of IL-17A-producing gd T cells [3].
Although IL-36a was also found to be up-regulated in
joints of patients with psoriatic and rheumatoid arthritis
[2], it seems to have no proinflammatory effect in this
context. In fact, in several experimental arthritis models,
IL-36g, IL-36Ra and IL-36R did not correlate with arthri-
tis severity and treatment with neutralizing antibodies
against IL-36R did not affect arthritis severity in collagen-
induced arthritis [5,6].
Primary Sj€ogren’s syndrome (pSS) is an autoimmune
disorder in which multiple activation of the innate
immune system and of B and T cells has been implicated
in disease pathogenesis [7]. In particular, activation of the
pathogenic IL-23/IL-17/IL-22 axis has been demonstrated
recently to be one of the key mediators of primary pSS
pathogenesis [8,9]. IL-36 receptor (IL-36R) signalling
appears to be absolutely crucial for the control of this
axis [10,11].
Despite the demonstrated relevance of the IL-23/IL-17/
IL-22 axis, the role of IL-36 and, in particular, the
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immunological behaviour of gd T cells in pSS, have not
so far been defined.
In the results included in this study, we show that IL-36,
but not IL-36R and IL-36 receptor antagonist (IL-36RA), is
strongly over-expressed in the salivary glands and in the
serum of pSS patients and correlated with the degree of tis-
sue inflammation. In addition, we show that gd T cells
strongly express the IL-36R and produce high levels of IL-
36 and IL-17, providing the first evidence of a putative
proinflammatory role of IL-171 IL-361 gd T lymphocytes
in the inflammatory responses of the disease.
Methods
Patients
Blood and minor labial salivary glands (MSG) biopsies
were obtained from 35 patients (30 female, mean age
436 12 years, mean disease duration 236 18 months) ful-
filling the American–European Consensus Group criteria
for pSS [12] and 20 patients (15 female, mean age 486 9
years, mean disease duration 286 14 months) displaying
subjective complaints of dry mouth or eyes, who did not
meet the American–European Consensus Group criteria
for pSS (nSS) and were considered as the control group. All
the nSS subjects had negative biopsy at histological assess-
ment. Disease activity was assessed by using the EULAR
Sj€ogren’s Syndrome Disease Activity Index (ESSDAI) [13].
All the patients and controls gave their informed consent
and the study was approved by the ethical committee of
the University of Palermo. Serological evaluations, which
included tests for the presence of anti-nuclear antibodies
(positive in 85% of pSS), anti-SSA/Ro/anti-SSB/La (posi-
tive in 71% of pSS), levels of CRP (146 6 mg/l in pSS ver-
sus 36 18 in controls, P < 005) and erythrocyte
sedimentation rate (ESR) (446 12 mm/h in pSS versus
126 6 in controls, P < 005) were performed. Multiple
minor labial salivary glands biopsies were obtained from all
the pSS patients and controls and placed into formalin fix-
ative and RNAlater for immunohistochemistry and reverse
transcription–polymerase chain reaction (RT–PCR) analy-
ses, respectively. Ten matched biopsies were also placed in
RPMI for isolation of salivary gland mononuclear cells
(SGMC) and flow cytometry analysis.
Histology and immunohistochemistry
Paraffin-embedded sections of 5-lm thickness were
stained with haematoxylin and eosin (H&E) for the histo-
logical evaluation of the presence of lymphocytic infil-
trates and/or foci. A focus was defined as an aggregate
of 50 lymphocytes and the focus score was reported as
the number of foci per 4 mm2 of tissue. Immunohisto-
chemistry was performed on 5-lm-thick paraffin-embed-
ded sections from salivary glands and from lymph nodes
used as positive controls, as described previously [14].
Lymph nodes were obtained from patients with lymphoa-
denomegaly undergoing biopsy for diagnostic purposes
suspecting lymphoproliferative diseases. Only lymph
nodes showing reactive lymphoid hyperplasia were used
for immunohistochemistry (IHC) experiments. The pri-
mary antibodies rabbit anti-human IL-36a and rabbit
anti-human IL-38 (Table 1) were added and incubated
for 1 h at room temperature. Isotype-matched irrelevant
antibodies were used as a negative control [rabbit immu-
noglobulin (Ig)G polyclonal antibody (ab27472); AbCam,
Cambridge, UK]. The number of positive cells was deter-
mined by counting the reactive cells on microphotographs
obtained from three randomly selected high-power
microscopic fields (original magnification 3400). To spe-
cifically address the nature of IL-36-producing cells,
double-staining for CD3/IL-36a, CD19/IL-36a and
CD68/IL-36a and triple staining for CD138/CD78/IL-36a
(Table 1) was performed on paraffin-embedded sections
of salivary glands and the sections were treated with fluo-
rescein isothiocyanate (FITC)-, Rhodamine Redor Cy-5-
conjugated anti-mouse or anti-rabbit antibodies (Invitro-
gen, Carlsbad, CA, USA) plus RNasi (200 ng/ml) and
counterstained using Toto-3 iodide (642/660; Invitrogen)
or 4’,6-diamidino-2-phenylindole (DAPI) (Life Technolo-
gies, Paisley, UK). Confocal analysis was used to acquire
fluorescence staining.
RNA extraction from salivary gland biopsies and
quantitative TaqMan RT–PCR
Soon after removal, salivary gland biopsies were also
stored in RNAlater
VR
solution (Applied Biosystems, Foster
City, CA, USA). RT–PCR was performed as described
previously [14]. Master mix and Taqman
VR
gene expres-
sion assays for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH control) and target genes IL-36A
(Hs00205367_m1), IL-36R (Hs00909276_m1), IL-36RA
(Hs01104220_g1) and IL-38 (Hs00544662_g1) were
obtained from Applied Biosystems (Foster City, CA,
USA). Data were quantified using SDS 21 software and
normalized using GAPDH as endogenous control. Rela-
tive changes in gene expression between nSS and pSS
samples were determined using the DDCt method. Levels
of the target transcript were normalized to a GAPDH
endogenous control, constantly expressed in both groups
(DCt). For DDCt values, additional subtractions were per-
formed between pSS (n5 35) and nSS (n = 20) DCt val-
ues. Final values were expressed as fold of induction.
Isolation of minor salivary gland mononuclear cells
and flow cytometry
Minor SGMCs were obtained as described previously
from 10 pSS and 10 nSS patients. Cell viability (trypan
blue dye exclusion) was always> 95%. Four-colour flow
IL-36a in Sj€ogren’s syndrome
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cytometry analysis was performed using a fluorescence
activated cell sorter (FACS)Calibur (BD Biosciences, San
Jose, CA, USA). At least 50 000 cells (events), gated on
the lymphocyte or monocyte/macrophage regions, were
acquired for each sample and data are presented as a per-
centage of total alive cells in the CD45 channel.
Enzyme-linked immunosorbent assay (ELISA) for
serum IL-36a
Serum IL-36a was assayed by commercial ELISA (Cusa-
bio Biotech, Wuhan, China).
Statistical analysis
Parametric and non-parametric statistical analysis was
performed calculating the mean6 standard error of the
mean (s.e.m.) and median, respectively. For comparison
of parametric and non-parametric data, the t-test and
Mann–Whitney rank-sum test were used where appropri-
ate. Spearman’s correlation analysis was utilized to quan-
tify the expression associations between the genes of
interest. Data are expressed as mean6 s.e.m. P-values less
than 005 were considered significant.
Results
IL-36a is over-expressed in pSS patients
The IL-36 axis was evaluated in MSG of pSS and nSS
patients. A significantly increased expression of IL-36 a
(Fig. 1a), but not of IL-36R (Fig. 1b), was found in pSS
salivary gland tissue, as detected by RT–PCR, and corre-
lated with those of IL-17, IL-22 and IL-23p19 (Support-
ing information, Fig. S1a–c; r25 045, r25 066, r25 073,
respectively; P < 005). IL-36a expression was also corre-
lated with the focus score (Fig. 1e). IL-36RA and IL-38,
both inhibitors of IL-36a, showed different behaviour, IL-
36RA being significantly down-regulated (Fig. 1c), and
IL-38 strongly over-expressed (Fig. 1d). Because of the
high expression in MSG, we next analysed IL-36a levels
in the serum of pSS patients. Serum IL-36a levels were
significantly higher in pSS compared to controls (mean-
6 s.e.m.: 4396 165 versus 886 47; P < 00001) (Fig. 1f).
Table 1. List of primers and antibodies
Primers and sequences and antibodies
IL-36 Hs00205367_m1 IL-36a Rabbit anti-human (1 : 100 dilution), (Sigma, St
Louis, MO, USA)
IL-36R Hs00909276_m1 gd PE anti-human gd (Becton Dickinson, San Jose,
CA, USA)
IL-36RA Hs00893626_m1 IL-17 PerCP/Cy5.5 anti-human IL-17A Antibody (Biole-
gend, San Diego, CA, USA)
IL-38 Hs00544662_g1 IFN-g FITC anti-human IFN-g antibody (Biolegend, San
Diego, CA, USA)
IL-17 Hs00174383_m1 IL-36a Mouse anti-human IL-36a (clone 162122, R&D,
Minneapolis, MN, USA)
IL-23p19 Hs00372324_m1 Anti-mouse
FITC
Rabbit anti-mouse FITC-conjugated (Sigma, St
Louis, MO, USA)
IL-22 Hs01574154_m1 IL-36R Rabbit anti-human IL-36R (Novus biologicals, Lit-
tleton, CO, USA)
CD138 Mouse anti-human (Dako, Glostrup, DK) (1 :
100 dilution)
Anti-rabbit
PerCP
Goat anti-rabbit PerCP-conjugated (Sigma, St
Louis, MO, USA)
CD68 Mouse anti-human (Dako, Glostrup, DK) (1 :
100 dilution)
CD68 Mouse anti-human CD68 PE-conjugated (Biole-
gend, San Diego, CA, USA)
CD78 Mouse anti-human (Dako, Glostrup, DK) (1 :
100 dilution)
CD3 Mouse anti-human CD4 PE-conjugated (Biole-
gend, San Diego, CA, USA)
CD19 Mouse anti-human (Dako, Glostrup, Denmark)
(1 : 100 dilution)
IL-38 Rabbit anti-human (1 : 50 dilution) Novus Biolog-
ical (Littleton, CO, USA)
CD3 Mouse anti-human (Dako, Glostrup, Denmark)
(1 : 100 dilution)
CD38 PE anti-human CD38 (Biolegend, San Diego, CA,
USA)
CD45 Mouse anti-human APC Cy7-conjugated (Biol-
egend, San Diego, CA, USA)
7-AAD Biolegend, San Diego, CA, USA
CD138 Mouse anti-human APC-conjugated (Biole-
gend, San Diego, CA, USA)
7-AAD5 7-aminoactinomycin D; APC5 allophycocyanin; PE5phycoerythrin; PerCP5 peridinin chlorophyll; FITC5 fluorescein isothiocya-
nate; IL5 interleukin; IFN5 interferon.
F. Ciccia et al.
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pSS patients segregate into two groups: those with nota-
bly elevated IL-36a (> 550 pg/ml) and those with little
or no IL-36a. Interestingly, pSS patients with higher IL-
36a serum levels manifest distinct profiles, showing
higher disease activity (Fig. 1g) and higher levels of
mRNA for IL-36 (Fig. 1h), IL-36R and IL-38 (data not
shown) compared to those with lower levels.
Immunohistochemical analysis of IL36a and IL-38
expression in pSS salivary glands
We next evaluated the protein expression and tissue dis-
tribution of IL-36a and IL-38 in the MSG. A significantly
higher expression of IL-36a was observed in pSS com-
pared to controls. In control subjects, IL-36a expression
was rarely detected and observed essentially among oval-
or fan-shaped cells with bi-lobed or multi-lobed nuclei
located closely to ducts, morphologically resembling
plasma cells (Fig. 2a). Conversely, in pSS the expression
of IL-36a was observed essentially in inflammatory infil-
trates among lymphoid cells, cells displaying dendritic
morphology and cells resembling plasma cells (Fig. 2b–e).
No significant acinar and/or ductal epithelial expression
of IL-36a was observed in patients and in controls (Figs
2a–e and 4b). The semi-quantitative analysis of IL-36a-
expressing cells revealed a significant positive correlation
between the number of IL-36a1 cells and the ratio
between the numbers of IL-36a1 cells and the total of
infiltrating mononuclear cells (Fig. 2g). We next evaluated
the expression of IL-38 in pSS patients and controls. As
shown in Fig. 2 h–k,m, IL-38 was also up-regulated in
the salivary glands of pSS, expressed mainly among acinar
epithelial cells and infiltrating mononuclear cells (Fig. 2i–
k). In control subjects, basal expression of IL-38 was also
observed in the context of ductal epithelial cells (Fig. 2h).
In order to study the cellular source of IL-36a among
infiltrating mononuclear cells, flow cytometry analysis of
isolated SGMCs and confocal microscopy analysis of
paraffin-embedded sections was also performed. As
shown in Fig. 3a,b, T cell receptor (TCR)-ab1 cells and
macrophages were the major source of IL-36a in SGMC,
with plasma cells accounting for only a small percentage
of IL-36a1 cells (the gating strategy is shown in Support-
ing information, Fig. S2). According to previous reports
[15–17], CD31 cells (Fig. 4a–c) and CD681 macrophages
(Fig. 4d,) were confirmed by confocal microscopy analysis
to express IL-36a in the salivary glands of pSS. Con-
versely, only a small percentage of B cells (Fig. 4f–h) and
plasma cells (Fig. 4i,j) expressed IL-36a.
gd1/IL-171IL-361T cells are expanded in the salivary
glands of pSS patients and correlated with the focus
score
Because of the role of IL-36a in modulating the function
of gd T cells in psoriasis [3] and the absence of studies
regarding their immunological behaviour in pSS, we next
analysed these innate cells in patients and controls using
Fig. 1. Interleukin (IL)-36a axis in primary
Sj€ogren’s syndrome (pSS) patients as assessed
using reverse transcription–polymerase chain
reaction (RT–PCR). (a–d) Relative m-RNA
quantification of IL-36a (a), IL-36R (b), IL-36RA
(c) and IL-38 (d) was assessed by quantitative
reverse transcription–polymerase chain reaction
(qRT–PCR) in minor salivary glands obtained
from 35 pSS patients and 20 control subjects. IL-
36a (a) and IL-38 (d) showed a significant over-
expression in pSS compared to controls.
Conversely, IL-36R expression was not modulated
between patients and controls (b), IL-36 RA
being down-regulated significantly (c). (e)
Correlation between IL-36a m-RNA expression
and the lymphocytic focus score. The r2
(r25 0.4122) and P (P < 00001) values were
determined with Spearman’s correlation
coefficient. (f) IL-36a levels detected in the
serum of pSS and controls by enzyme-linked
immunosorbent assay (ELISA) (*P < 00001). (g)
IL-36a serum levels according to EULAR
Sj€ogren’s Syndrome Disease Activity Index
(ESSDAI) scores.
IL-36a in Sj€ogren’s syndrome
VC 2015 British Society for Immunology, Clinical and Experimental Immunology, 181: 230–238 233
flow cytometry (the gating strategy is shown in Support-
ing information, Fig. S2). No significant expansion of gd
T cells was observed in pSS compared to controls
(386 07 versus 316 08; P> 005) (data not shown);
gd T cells from pSS patients, however, produced higher
amounts of IL-17 compared to controls (4276 03 versus
0736 004; P < 0005) (Fig. 5a–c). Although numerically
not expanded compared to controls, the percentages of
gd T cells in pSS was correlated significantly with the
focus score (Fig. 5j). Conversely, no difference in gd1/
IFN-g1 T cell levels in pSS and controls [0346 022 ver-
sus 0216 011, P = not significant (n.s.), data not
shown] was observed. Notably, a significantly higher
percentage of gd1 T cells from pSS patients co-expressed
IL-17 and IL-36a (356 05% versus 0456 001%,
P < 0001) (Fig. 5d–f) and the IL-36R (4076 07% in
pSS versus 0816 04% in nSS; P < 0005) (Fig. 5g–i),
suggesting a possible autocrine stimulatory loop.
Discussion
In this study we demonstrate for the first time, to our
knowledge, that the IL-36 axis is modulated in pSS and
probably involved in the control of the IL-23/IL-17/IL-22
axis, as demonstrated previously in other autoimmune dis-
eases [18,19], and suggest a role for gd1/IL-171/IL-36a1
in the pathogenesis of pSS.
IL-36a is a member of the IL-1 cytokine family,
expressed mainly in keratinocytes, bronchial epithelium,
Fig. 2. Interleukin (IL)-36a and IL-38 expression in primary Sj€ogren’s syndrome (pSS) patients’ minor salivary glands as assessed by
immunohistochemistry. Representative microphotographs showing IL-36a immunostainings in 20 control subjects and 35 pSS patients. (a) IL-
36a expression in minor salivary glands of controls. (b–e) IL-36a expression in the minor salivary glands of pSS patients with different focus
score: focus scores 2 (b), 3 (c) and 4 (d,e). (f) Representative microphotographs showing minor salivary gland sections of a patient with pSS and
focus score 4 stained with control isotype antibody. (g) Correlation of IL-36a1 cells with the focus scores. Number of IL-36a-expressing cells
was correlated with the ratio between the number of IL-361 cells and the number of infiltrating mononuclear cells in minor salivary glands of
pSS. The r2 (r25 05460) and P (P = 00002) values were determined with Spearman’s correlation coefficient. (h–k) Representative
microphotographs showing IL-38 immunostainings in 20 control subjects and 35 pSS patients. (h) In control subjects IL-38 was observed
exclusively among ductal epithelial cells. (i–k) In pSS patients a strong expression of IL-38 was observed among acinar epithelial cells and
infiltrating mononuclear cells. (l) Representative microphotographs showing minor salivary gland sections of a patient with pSS and focus score
4 stained with control isotype antibody. (m) Quantification of IL-381 cells in pSS and non-Sj€ogren’s syndrome patients (nSS). (a–d,f,h–j,l)
Original magnification 3250; (e,k) original magnification 3400.
F. Ciccia et al.
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brain tissue, monocytes/macrophages ab and gd T lym-
phocytes [1]. IL-36a signals through a heterodimeric
complex consisting of the IL-1 receptor accessory protein
[10]. Ligation of IL-36a with its cognate receptor seems
to induce proinflammatory responses, being potentially
involved in the pathogenesis of systemic autoimmune dis-
eases such as rheumatoid arthritis and psoriasis [2,3]. In
particular, IL-36a has been proposed as a central regula-
tor of human immune responses acting in the interface
between innate and adaptive immunity by expanding
both IL-171 gd T cells and IL-171 ab T cells [3,17,20].
The immune effects of IL-36a seem to be antagonized by
two different IL-36R ligands, IL-36RA and IL-38. Ligation
of IL-36RA and/or of IL-38 with the IL-36R may, in fact,
reverse the proinflammatory properties of IL-36a [21].
In our study, levels of IL-36a were increased signifi-
cantly in the serum and salivary glands of pSS patients.
Serum levels of IL-36a were increased significantly in pSS
patients and correlated with disease activity, suggesting a
potential role of IL-36a dosage in monitoring the activa-
tion of the immune system in pSS. Salivary gland IL-36a
was correlated significantly with the level of tissue inflam-
mation and detected, in particular, in the infiltrating cells
only, being virtually absent among ductal and acinar epi-
thelial cells. Using flow cytometry and confocal micros-
copy analysis, these cells were confirmed to be, to a larger
extent, ab1 CD31 T lymphocytes and CD681 macro-
phages. Plasma cells were also confirmed, however, to be
a tissue source of IL-36a in both pSS and controls. Tissue
IL-36a levels also correlated with the expression of IL-17,
IL-22 and IL-23p19. Despite the high levels of IL-36a
observed, IL-36R was not up-regulated in pSS, suggesting
that the physiological basal expression of IL-36R might be
not increased further under inflammatory stimuli. Several
Fig. 3. Interleukin (IL)-36a is expressed by T
cells and macrophages in the salivary glands of
primary Sj€ogren’s syndrome (pSS) patients.
Salivary glands mononuclear cells were isolated
from biopsies obtained from 10 pSS patients and
10 controls. (a) Representative dot-plots showing
IL-36a expression by T cell receptor (TCR)-ab1,
CD681 and CD138 cells. (b) Percentages of IL-
36a-producing cells among TCRab1, CD681
and CD138 cells in pSS patients and controls.
IL-36a in Sj€ogren’s syndrome
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studies support the dual regulation of the two known
inhibitors of IL-36a, IL-36RA and IL-38 in autoimmune
diseases (reviewed in [22]). In our study, IL-36RA and
IL-38 were modulated differently in pSS. IL-36RA was, in
fact, down-regulated significantly, suggesting an imbal-
ance in IL-36 response in pSS. Conversely, IL-38 was up-
regulated significantly suggesting, in our opinion, the
occurrence of an attempt by the immune system to coun-
teract the imbalanced activation of IL-36.
gd T cells represent a small subset of T cells that pos-
sess a distinct TCR on their surface and are considered to
be located at the border between the more evolutionarily
primitive innate immune system and the more evolved
adaptive immune system [23]. Similarly to ab T cells, gd
T cells have been demonstrated to be polarized into T
helper type 17 (Th17) (producing only IL-17), Th1/17
(producing both IFN-g and IL-17) and Th22 (producing
only IL-22) populations, with distinct cytokines required
for their initial polarization and later maintenance [23].
These data indicate that gd T cells participate in both the
regulation and the propagation of murine lupus.
IL-36a has been proved to promote the expansion
and the production of IL-17 by gd1 T cells in psoriatic
skin [3]. In this study we provide the first demonstra-
tion that, in pSS, gd1 T cells isolated from the salivary
glands, although not significantly expanded, are corre-
lated with the lymphocytic focus score. gd1 T cells were
only a small percentage of infiltrating T cells in pSS,
but they appeared to be activated because of their
expression of high levels of IL-36R and the production
of higher levels of IL-17 and IL-36a. The absence of
IFN-g production suggests the presence of specific and
coordinate regulation of effector gd1 T cells functions.
gd1 T cells seem to participate in both the regulation
and the propagation of systemic autoimmunity [24] to
be the major IL-17 producers in the skin of patients
with psoriasis and to promote adaptive immune
response by promoting a Th1 response [25]. Our find-
ings may suggest that activated IL-36R1IL-171 gd1 T
cells might be a specific feature of pSS contributing to
adaptive and immune responses in pSS and highlight
the importance of innate sources of IL-17 in the patho-
genesis of disease.
In conclusion, in this study we demonstrate that a sig-
nificant increase in circulating and tissue levels of IL-36a
occurs in pSS. Further studies, however, are required to
Fig. 4. Confocal analysis of cells expression of
interleukin (IL)-36a in minor labial salivary
glands (MSGs). (a,b) Representative images of
confocal analysis of IL-36a and CD3 co-
localization in salivary glands of pSS patients.
Salivary gland (SG) epithelial cells do not show
IL-36a epithelial staining (b). Nuclei were
counterstained with toto-3 (blue). (c) Number of
CD31IL-361 cells in primary Sj€ogren’s syndrome
(pSS) patients and controls. (d) Representative
image of confocal analysis of IL-36a and CD68
co-localization in salivary glands of pSS patients.
Nuclei were counterstained with toto-3 (blue).
(d) Quantification of CD681IL-36a1 cells in pSS
patients and controls. (f–g) Representative images
of confocal analysis of IL-36a and CD19 co-
localization in salivary glands of pSS patients.
Nuclei were counterstained with toto-3 (blue).
(h) Quantification of CD191IL-36a1/CD191
cells in pSS patients and controls. (i)
Representative image of confocal analysis of IL-
36a, CD78 and CD138 co-localization in salivary
glands of pSS patients. (i) Percentages of
CD381IL-361 cells in pSS and non-Sj€ogren’s
syndrome patients (nSS) as assessed by flow
cytometry. Data are shown as mean6 standard
error of the mean.
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define more clearly the role of IL-36a in pSS pathogenesis
and in the modulation of gd1 T cell immune functions.
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Fig. S1. Correlation between proinflammatory cytokines
and IL-36a. (b) Correlation between interleukin (IL)-17
and IL-36a m-RNA expression. (b) Correlation between
IL-22 and IL-36a m-RNA expression. (c) Correlation
between IL-23p19 and IL-36a m-RNA expression. The r2
and P-values were determined with Spearman’s correla-
tion coefficient.
Fig. S2. Gating strategy for flow cytometry analysis. In
this sample gating, cells were first gated for lymphocytes
[side-scatter (SSC)-A versus forward scatter (FSC)-A] and
the lymphocyte gate analysed further for CD45 expression
and for uptake of 7-aminoactinomycin D (7AAD) to
determine live versus dead cells.
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